» Articles » PMID: 37569787

Epithelial-Mesenchymal Transition Mechanisms in Chronic Airway Diseases: A Common Process to Target?

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Aug 12
PMID 37569787
Authors
Affiliations
Soon will be listed here.
Abstract

Epithelial-to-mesenchymal transition (EMT) is a reversible process, in which epithelial cells lose their epithelial traits and acquire a mesenchymal phenotype. This transformation has been described in different lung diseases, such as lung cancer, interstitial lung diseases, asthma, chronic obstructive pulmonary disease and other muco-obstructive lung diseases, such as cystic fibrosis and non-cystic fibrosis bronchiectasis. The exaggerated chronic inflammation typical of these pulmonary diseases can induce molecular reprogramming with subsequent self-sustaining aberrant and excessive profibrotic tissue repair. Over time this process leads to structural changes with progressive organ dysfunction and lung function impairment. Although having common signalling pathways, specific triggers and regulation mechanisms might be present in each disease. This review aims to describe the various mechanisms associated with fibrotic changes and airway remodelling involved in chronic airway diseases. Having better knowledge of the mechanisms underlying the EMT process may help us to identify specific targets and thus lead to the development of novel therapeutic strategies to prevent or limit the onset of irreversible structural changes.

Citing Articles

Modulation of the Epithelial-mesenchymal transition process by Forkhead Box C2 in the repair of airway epithelium after injury.

Wang Y, Liu J Respir Res. 2025; 26(1):96.

PMID: 40065336 PMC: 11895206. DOI: 10.1186/s12931-025-03150-8.


Role of E-cadherin in epithelial barrier dysfunction: implications for bacterial infection, inflammation, and disease pathogenesis.

Lialios P, Alimperti S Front Cell Infect Microbiol. 2025; 15:1506636.

PMID: 40007608 PMC: 11850337. DOI: 10.3389/fcimb.2025.1506636.


Immunomodulatory Significance of Mast Cell Exosomes (MC-EXOs) in Immune Response Coordination.

Elieh-Ali-Komi D, Shafaghat F, Alipoor S, Kazemi T, Atiakshin D, Pyatilova P Clin Rev Allergy Immunol. 2025; 68(1):20.

PMID: 39976807 PMC: 11842441. DOI: 10.1007/s12016-025-09033-6.


Identification of a vimentin-expressing α-cell phenotype in CF and normal pancreas.

Kattner N, Hang Y, Krentz N, Krentz N, Russell L, Palmer M J Endocrinol. 2025; 264(3).

PMID: 39836539 PMC: 11850051. DOI: 10.1530/JOE-24-0190.


Regulatory mechanisms of haptoglobin on particulate matter-induced epithelial-to-mesenchymal transition in bronchial epithelial cells.

Qian Y, Fang C, Wang B, Xu Z, Yu W, Gritsiuta A J Thorac Dis. 2025; 16(12):8724-8742.

PMID: 39831254 PMC: 11740073. DOI: 10.21037/jtd-2024-2013.


References
1.
Ghigo A, de Santi C, Hart M, Mitash N, Swiatecka-Urban A . Cell signaling and regulation of CFTR expression in cystic fibrosis cells in the era of high efficiency modulator therapy. J Cyst Fibros. 2023; 22 Suppl 1:S12-S16. DOI: 10.1016/j.jcf.2022.12.015. View

2.
Trojan T, Alejandre Alcazar M, Fink G, Thomassen J, Maessenhausen M, Rietschel E . The effect of TGF-β polymorphisms on pulmonary disease progression in patients with cystic fibrosis. BMC Pulm Med. 2022; 22(1):183. PMC: 9080196. DOI: 10.1186/s12890-022-01977-1. View

3.
Conese M, Di Gioia S . Pathophysiology of Lung Disease and Wound Repair in Cystic Fibrosis. Pathophysiology. 2022; 28(1):155-188. PMC: 8830450. DOI: 10.3390/pathophysiology28010011. View

4.
Carroll N, Perry S, Karkhanis A, Harji S, Butt J, James A . The airway longitudinal elastic fiber network and mucosal folding in patients with asthma. Am J Respir Crit Care Med. 2000; 161(1):244-8. DOI: 10.1164/ajrccm.161.1.9805005. View

5.
Osei E, Mostaco-Guidolin L, Hsieh A, Warner S, Al-Fouadi M, Wang M . Epithelial-interleukin-1 inhibits collagen formation by airway fibroblasts: Implications for asthma. Sci Rep. 2020; 10(1):8721. PMC: 7250866. DOI: 10.1038/s41598-020-65567-z. View